Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aleix Prat

Showing results (21-30 of 326) with videos related to

Pageof 33
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 27, 2008
Acute severe hypothyroidism induced by sunitinibAleix Prat, César Serrano, Claudia Valverde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2013
Reply to Y.Yamamoto et alAleix Prat, Miguel Martin, Torsten O Nielsen, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|December 1, 2020
Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's boxPaolo Tarantino, Aleix Prat, Javier Cortes, et al.
Current Medical Research and Opinion|January 26, 2016
Value of a gene signature assay in patients with early breast cancer and intermediate risk: a single institution retrospective studyJacques Bonneterre, Aleix Prat, Patricia Galván, et al.
NPJ Breast Cancer|July 19, 2022
A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypesFrancesco Schettini, Fara Brasó-Maristany, Nicole M Kuderer, et al.
Cancer Treatment Reviews|December 23, 2022
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancerClaudette Falato, Francesco Schettini, Tomás Pascual, et al.
Journal for Immunotherapy of Cancer|March 30, 2019
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancerGaia Griguolo, Tomás Pascual, Maria Vittoria Dieci, et al.
European Journal of Cancer (Oxford, England : 1990)|May 4, 2023
Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysisGuillermo Villacampa, Alexios Matikas, Mafalda Oliveira, et al.
Gynecologic Oncology|June 12, 2008
Update on novel therapeutic agents for cervical cancerJosep Maria del Campo, Aleix Prat, Antonio Gil-Moreno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2020
What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?Mariana Brandão, Rafael Caparica, Luca Malorni, et al.
Pageof 33

Showing results (21-30 of 326) with videos related to

Sort By:
Pageof 33
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 27, 2008
Acute severe hypothyroidism induced by sunitinibAleix Prat, César Serrano, Claudia Valverde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2013
Reply to Y.Yamamoto et alAleix Prat, Miguel Martin, Torsten O Nielsen, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|December 1, 2020
Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's boxPaolo Tarantino, Aleix Prat, Javier Cortes, et al.
Current Medical Research and Opinion|January 26, 2016
Value of a gene signature assay in patients with early breast cancer and intermediate risk: a single institution retrospective studyJacques Bonneterre, Aleix Prat, Patricia Galván, et al.
NPJ Breast Cancer|July 19, 2022
A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypesFrancesco Schettini, Fara Brasó-Maristany, Nicole M Kuderer, et al.
Cancer Treatment Reviews|December 23, 2022
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancerClaudette Falato, Francesco Schettini, Tomás Pascual, et al.
Journal for Immunotherapy of Cancer|March 30, 2019
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancerGaia Griguolo, Tomás Pascual, Maria Vittoria Dieci, et al.
European Journal of Cancer (Oxford, England : 1990)|May 4, 2023
Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysisGuillermo Villacampa, Alexios Matikas, Mafalda Oliveira, et al.
Gynecologic Oncology|June 12, 2008
Update on novel therapeutic agents for cervical cancerJosep Maria del Campo, Aleix Prat, Antonio Gil-Moreno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2020
What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?Mariana Brandão, Rafael Caparica, Luca Malorni, et al.
Pageof 33